ALL. B ai fini della pubblicazione

Decreto Rettore Università di Roma "La Sapienza" n 3227/2021 del 02.12.2021
Procedura selettiva di chiamata per n. 1 posto di Ricercatore a tempo determinato - Tipologia B presso il Dipartimento di Medicina Molecolare, Facoltà di Farmacia e Medicina, Settore Scientifico-disciplinare MED/04, Settore concorsuale 06/A2, codice concorso 2021RTDB023.

VALENTINA SILVESTRI
Curriculum Vitae

Roma, 26/01/2022

Part I – Education

Type	Year	Institution	Notes (Degree, Experience,…)
University graduation	2007	Sapienza Università di Roma	Laurea Triennale in Scienze Biologiche. Esperienza in biologia cellulare e molecolare.
University graduation	2009	Sapienza Università di Roma	Laurea Specialistica in Genetica e Biologia Molecolare. Esperienza in genetica, patologia molecolare ed oncologia molecolare.
PhD	2013	Sapienza Università di Roma	PhD in Dermatologia, Anatomia, Chirurgia Plastica. Esperienza in epidemiologia molecolare del cancro.
Post-doctorate studies	2013	Sapienza Università di Roma	Corso di Alta Formazione in Metodi Statistici per la ricerca e la pratica biomedica. Esperienza in biostatistica.
Post-doctorate studies	2014	Sapienza Università di Roma	Master in Bioinformatica: applicazioni biomediche e farmaceutiche. Esperienza in analisi dati biomolecolari applicata all'oncologia.
Post-doctorate studies	2015	King's College, London (UK)	Translational Bioinformatics Workshop. Esperienza in analisi bioinformatica di dati.

Part II – Appointments

IIA – Academic Appointments

Start	End	Institution	Position
01/02/2016	31/01/2022	Sapienza Università di Roma, Dipartimento di Medicina Molecolare	Assegnista di Ricerca, SSD MED/04
07/2014	08/2014	Department of Public Health and Primary Care, University of Cambridge (UK)	Visiting Fellow
01/2013	12/2015	Sapienza Università di Roma, Dipartimento di Medicina Molecolare	Borsista FIRC (Fondazione Italiana per la Ricerca sul Cancro)

11/2009	10/2012	Sapienza Università di Roma, Dipartimento di Medicina Molecolare	Borsista di Dottorato

IIB – Other Appointments

Start	End	Institution	Position
05/2021	05/2030	Ministero dell'istruzione, dell'Università e della Ricerca (MIUR) - ANVUR	Abilitazione Scientifica Nazionale a Professore di II fascia nel Settore Concorsuale 06/A2 – SSD MED/04 – Sesto Quadrimestre
11/2020	11/2029	Ministero dell'istruzione, dell'Università e della Ricerca (MIUR) - ANVUR	Abilitazione Scientifica Nazionale a Professore di II fascia nel Settore Concorsuale 06/N1 – SSD MED/46 - Quinto Quadrimestre
09/2021	06/2022	Cancers	Guest Editor, Special Issue **"**Hereditary Breast Cancer in Men and Women: Genetic Mutations, Cancer Risk and Treatment"
11/2020	12/2021	International Journal of Molecular Sciences	Guest Editor, Special Issue "Advances in the molecular basis of BRCA-associated cancers"
02/2021	In corso	Frontiers in Genetics	Editorial Board Member
05/2019	In corso	Frontiers in Oncology	Editorial Board Member

Part III – Teaching experience

Year	Institution	Lecture/Course
2021	Sapienza Università di Roma, Dipartimento di Medicina Molecolare	Master di II livello in Virologia Molecolare. Insegnamenti: "Tecniche di sequenziamento di ultima generazione NGS"; "Analisi dei dati di NGS".
2021	Sapienza Università di Roma, Dipartimento di Scienze Odontostomatologiche e Maxillo Facciali	Master di II livello in Rino-Allergologia Pratica. Insegnamenti: "Basi genetiche delle patologie allergiche dell'apparato respiratorio"; "Basi genetiche delle ipersensibilità alimentari".
2020	Sapienza Università di Roma, Dipartimento di Medicina Molecolare	Incarico di insegnamento (1CFU) del Corso "Medicina Molecolare: tecnologie di diagnostica molecolare. Oncologia molecolare". Corso di Dottorato di Ricerca in Medicina Molecolare, I anno (XXXVI ciclo).
2018-in corso	Sapienza Università di Roma, Facoltà di Farmacia e Medicina	Cultrice della materia per l'insegnamento "Metodologia Medico-Scientifica Pre-Clinica", Corso di Laurea Magistrale in Medicina e Chirurgia, C.
2016-2017	Sapienza Università di Roma, Facoltà di Farmacia e Medicina	Cultrice della materia per l'insegnamento "Metodologia Medico-Scientifica di Base", Corso di Laurea Magistrale in Medicina e Chirurgia, C.

Part IV – Awards, Honors and Society memberships

Year	Title
2022	Fondazione Umberto Veronesi Post-Doctoral Fellowship Award 2022
2021	Titolo di "World Expert" dalla piattaforma Expertscape come top 0.1% dei migliori studiosi negli ultimi 10 anni nel topic "Male Breast Neoplasms" https://twitter.com/Daily_Experts/status/1451095435825795073?ref_src=twsrc%5Etfw
2012	FIRC triennial Fellowship Award "Mario e Valeria Rindi"
2011	Travel Grant Award per la partecipazione al convegno scientifico "Hereditary Breast and Ovarian Cancer (HBOC), 14-17 Settembre 2011, New York (USA)
2016-in corso	Membro del "PALB2 interest group"
2014-in corso	Membro del "Consortium of Investigators of Modifiers of BRCA1/2" (CIMBA)
2014-in corso	Membro del "Consorzio Italiano Tumori Ereditari alla Mammella" (CONSIT TEAM)
2010-in corso	Membro dello "Studio Multicentrico Italiano sul Carcinoma Mammario Maschile"
2010-in corso	Membro delle seguenti società scientifiche: Società italiana di cancerologia (SIC); Associazione europea per la ricerca sul cancro (EACR); Società italiana di patologia e medicina traslazionale (SIPMET); Società europea di genetica umana (ESHG); Società americana di genetica umana (ASHG)

Part V - Funding Information [grants as PI-principal investigator or I-investigator]

Year	Title	Program	Grant value
2021	Dissecting transcriptomic-based immunophenotypes in male breast cancer.	Ricerca di Ateneo Sapienza Università di Roma AR22117A5C354C3A **(PI)**	2.250 €
2020	Analysis of Tumor Mutational Burden in Male Breast Cancers characterized for germline mutations in homologous recombination genes.	Ricerca di Ateneo Sapienza Università di Roma RM120172B7A66A2D. **(I)**	10.000 €
2020	Germline and somatic characterization of male breast cancer for new molecular biomarker discovery	Lega Italiana per la Lotta contro i Tumori (LILT) - Programma 5 per mille anno 2019 Investigator Grant. **(I)**	40.000 €
2019	New players in the Homologous Recombination pathway: investigating the role of SMYD3 in breast cancers characterized for BRCA mutation status.	Ricerca di Ateneo Sapienza Università di Roma RM11916B7A575951. **(I)**	10.000 €
2018	Matched germline and tumor profiling in BRCA and non-BRCA male breast cancer for new molecular biomarker discovery.	AIRC IG #21389 5 year-project. **(I)**	872.000 €
2018	Providing insights into the transcriptome profile of *BRCA* mutation-positive and -negative male breast cancer.	Ricerca di Ateneo Sapienza Università di Roma RM118164360F928D. **(I)**	10.000 €
2017	*BRCA* and beyond: a case-control study investigating the role of unexpected mutations in DNA repair related genes as breast cancer risk factors in men	Avvio alla ricerca, Sapienza Università di Roma AR21715C357BFFA7. **(PI)**	2.000 €

2016	Evaluation of common genetic variants and their combined effect in male breast cancer risk	Avvio alla ricerca, Sapienza Università di Roma AR216154C95D6AAF. **(PI)**	2.000 €
2015	Integrative "omics" approach to the characterization of *BRCA*-positive and *BRCA*-negative male breast cancer	AIRC IG #16933 3 year-project. **(I)**	683.000 €
2012	Genetic and Epigenetic signatures of *BRCA*-positive and *BRCA*-negative Male Breast Cancer	AIRC IG #12780 3 year-project. **(I)**	450.000 €
2009	Genetic and epigenetic signatures of male breast cancer: a multicenter study in Italy	AIRC IG #8713 3 year-project. **(I)**	300.000 €

Part VI – Participation to scientific meetings as speaker

Year	Title of the presentation	Scientific meeting
2021	Transcriptome-Based Profiles of Immune Cell Infiltration in BRCA1/2-Positive and BRCA1/2-Negative Male Breast Cancers	BRCA 2021: The 8th International Symposium on Hereditary Breast and Ovarian Cancer; Virtual edition, 4-7 Maggio 2021
2014	Whole Exome Sequencing revealed a novel PALB2 mutation in a male breast cancer family	56th Annual Meeting of Italian Cancer Society (SIC); Ferrara, 11-13 Settembre 2014.
2013	Genetic susceptibility in male breast cancer: a multicenter study in Italy	SIPMET Young Scientist Meeting; Roma, 23-24 Ottobre 2013.
2010	Suscettibilità genetica al carcinoma mammario maschile: analisi mutazionale dei geni BRCA1, BRCA2, CHEK2, PALB2, BRIP1 e RAD51C	Congresso “Tumori Ereditari: dalla Biologia Molecolare al trattamento”, Modena 18-19 Novembre 2010.

Part VII – Research Activities

Keywords	Brief Description
Cancer Genetics Hereditary Tumors Familial Tumors Solid Tumors Molecular Oncology Bioinformatics Biostatistics	L'attività di ricerca della Dott.ssa Valentina Silvestri è principalmente rivolta alla genetica e all'epidemiologia molecolare dei tumori solidi, con particolare interesse per i carcinomi eredo-familiari. I suoi studi principali sono focalizzati sull'identificazione e la caratterizzazione di fattori di rischio genetico e di meccanismi molecolari coinvolti nell’insorgenza e nella progressione tumorale, nell'ambito di collaborazioni nazionali e internazionali, mediante l’utilizzo di tecnologie di ultima generazione. L’attività di ricerca è basata sulla particolare *expertise* della Dott.ssa Silvestri, sia nei metodi sperimentali della biologia molecolare, sia nell’analisi bioinformatica e biostatistica applicata all’oncologia, con l’utilizzo di *pipeline* per analisi di sequenziamento e di software statistici quali R e STATA. La sua linea di ricerca principale attualmente riguarda la caratterizzazione della suscettibilità genetica, delle caratteristiche patologiche e molecolari del carcinoma mammario eredo-familiare, ed in particolare del carcinoma mammario maschile.
	• Screening genomico mediante tecnologie di sequenziamento di nuova generazione (NGS), per l’identificazione di nuovi geni di suscettibilità.
	• Studio di varianti genetiche di suscettibilità mediante studi GWAS (*Genome Wide Association Studies*) condotti nell'ambito di consorzi internazionali.
	• Sviluppo di PRS (*Polygenic Risk Scores*) per la valutazione del rischio poligenico di sviluppare tumori.
	• Caratterizzazione dello spettro di tumori e della stima del rischio associato ai

principali geni di suscettibilità ai carcinomi ereditari, tra cui *BRCA1*, *BRCA2* e *PALB2.*
• Caratterizzazione molecolare dei tumori solidi: identificazione di mutazioni somatiche associate alla tumorigenesi, analisi di trascrittomica per l'identificazione di sottotipi molecolari, espressione di miRNA per la valutazione della progressione metastatica.

Part VIII – Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
Papers [international]	45	Pubmed	2010	2022
Papers [national]	-			
Books [scientific]	-			
Books [teaching]	-			

Total Impact factor	301.6 (relative to the publication year)
Average Impact factor per Product	6.7 (relative to the publication year)
Total Citations	824 (Scopus)
Average Citations per Product	18.3
Hirsch (H) index	17 (Scopus)
Normalized H index*	1.4

*H index divided by the academic seniority.

Part IX– Selected Publications

List of the publications selected for the evaluation. For each publication report title, authors, reference data, journal IF* (if applicable), citations**, press/media release (if any).

* Relative to the publication year
** from Scopus

1. Li S*, **Silvestri V***, Leslie G, Rebbeck TR, Neuhausen SL, Hopper JL, Nielsen HR, Lee A, Yang X, McGuffog L, Parsons MT, Andrulis IL, Arnold N, Belotti M, Borg Å, Buecher B, Buys SS, Caputo SM, Chung WK, Colas C, Colonna SV, Cook J, Daly MB, de la Hoya M, de Pauw A, Delhomelle H, Eason J, Engel C, Evans DG, Faust U, Fehm TN, Fostira F, Fountzilas G, Frone M, Garcia-Barberan V, Garre P, Gauthier-Villars M, Gehrig A, Glendon G, Goldgar DE, Golmard L, Greene MH, Hahnen E, Hamann U, Hanson H, Hassan T, Hentschel J, Horvath J, Izatt L, Janavicius R, Jiao Y, John EM, Karlan BY, Kim SW, Konstantopoulou I, Kwong A, Laugé A, Lee JW, Lesueur F, Mebirouk N, Meindl A, Mouret-Fourme E, Musgrave H, Ngeow Yuen Yie J, Niederacher D, Park SK, Pedersen IS, Ramser J, Ramus SJ, Rantala J, Rashid MU, Reichl F, Ritter J, Rump A, Santamariña M, Saule C, Schmidt G, Schmutzler RK, Senter L, Shariff S, Singer CF, Southey MC, Stoppa-Lyonnet D, Sutter C, Tan Y, Teo SH, Terry MB, Thomassen M, Tischkowitz M, Toland AE, Torres D, Vega A, Wagner SA, Wang-Gohrke S, Wappenschmidt B, Weber BHF, Yannoukakos D, Spurdle AB, Easton DF, Chenevix-Trench G, Ottini L, Antoniou AC. *Cancer Risks Associated with BRCA1 and BRCA2 Pathogenic Variants.* J Clin Oncol. 2022 Jan 25:JCO2102112. doi: 10.1200/JCO.21.02112 (*co-first authors). IF: 44.544.
Citations: 0
PRESS/MEDIA RELEASE:
https://medicalxpress.com/news/2022-01-faulty-brca-genes-linked-prostate.html

2. Barnes DR*, **Silvestri V***, Leslie G, McGuffog L, Dennis J, Yang X, Adlard J, Agnarsson BA, Ahmed M, Aittomäki K, Andrulis IL, Arason A, Arnold N, Auber B, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Barwell J, Belotti M, Benitez J, Berthet P, Boonen SE, Borg Å, Bozsik A, Brady A, Brennan P, Brewer C, Brunet J, Bucalo A, Buys SS, Caldés T, Caligo MA, Campbell I, Cassingham H, Lotte Christensen L, Cini G, Claes KBM; GEMO Study Collaborators; EMBRACE Collaborators, Cook J, Coppa A, Cortesi L, Damante G, Darder E, Davidson R, de la Hoya M, De Leeneer K, de Putter R, Del Valle J, Diez O, Chun Ding Y, Domchek SM, Donaldson A, Eason J, Eeles R, Engel C, Gareth Evans D, Feliubadaló L, Fostira F, Frone M, Frost D, Gallagher D, Gehrig A, Giraud S, Glendon G, Godwin AK, Goldgar DE, Greene MH, Gregory H, Gross E, Hahnen E, Hamann U, Hansen TVO, Hanson H, Hentschel J, Horvath J; KConFab Investigators; HEBON Investigators, Izatt L, Izquierdo A, James PA, Janavicius R, Birk Jensen U, Johannsson OT, John EM, Kramer G, Kroeldrup L, Kruse TA, Lautrup C, Lazaro C, Lesueur F, Lopez-Fernández A, Mai PL, Manoukian S, Matrai Z, Matricardi L, Maxwell KN, Mebirouk N, Meindl A, Montagna M, Monteiro AN, Morrison PJ, Muranen TA, Murray A, Nathanson KL, Neuhausen SL, Nevanlinna H, Nguyen-Dumont T, Niederacher D, Olah E, Olopade OI, Palli D, Parsons MT, Sokilde Pedersen I, Peissel B, Perez-Segura P, Peterlongo P, Petersen AH, Pinto P, Porteous ME, Pottinger C, Angel Pujana M, Radice P, Ramser J, Rantala J, Robson M, Rogers MT, Rønlund K, Rump A, María Sánchez de Abajo A, Shah PD, Sharif S, Side LE, Singer CF, Stadler Z, Steele L, Stoppa-Lyonnet D, Sutter C, Yen Tan Y, Teixeira MR, Teulé A, Thull DL, Tischkowitz M, Toland AE, Tommasi S, Toss A, Trainer AH, Tripathi V, Valentini V, van Asperen CJ, Venturelli M, Viel A, Vijai J, Walker L, Wang-Gohrke S, Wappenschmidt B, Whaite A, Zanna I, Offit K, Thomassen M, Couch FJ, Schmutzler RK, Simard J, Easton DF, Chenevix-Trench G, Antoniou AC, Ottini L; Consortium of Investigators of Modifiers of BRCA1 and BRCA2. *Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.* J Natl Cancer Inst. 2021 Jul 28:djab147. doi: 10.1093/jnci/djab147. (*co-first authors).
IF: 13.506
Citations: 0
PRESS/MEDIA RELEASE:
https://www.uniroma1.it/it/notizia/tumori-della-mammella-e-della-prostata-uomini-con-mutazione-dei-geni-brca-stime-di-rischio
https://tg24.sky.it/salute-e-benessere/2021/08/17/uomini-tumori-fattori-genetici

3. Zelli V, **Silvestri V**, Valentini V, Bucalo A, Rizzolo P, Zanna I, Bianchi S, Coppa A, Giannini G, Cortesi L, Calistri D, Tibiletti MG, Fox SB, kConFab, Palli D, Ottini L. *Transcriptome of male breast cancer matched with germline profiling reveals novel molecular subtypes with possible clinical relevance*. Cancers 2021, 13(18), 4515. doi: 10.3390/cancers13184515.
IF: 6.639
Citations: 0

4. Maguire S, Perraki E, Tomczyk K, Jones ME, Fletcher O, Pugh M, Winter T, Thompson K, Cooke R; kConFab Consortium, Trainer A, James P, Bojesen S, Flyger H, Nevanlinna H, Mattson J, Friedman E, Laitman Y, Palli D, Masala G, Zanna I, Ottini L, **Silvestri V**, Hollestelle A, Hooning MJ, Novaković S, Krajc M, Gago-Dominguez M, Castelao JE, Olsson H, Hedenfalk I, Saloustros E, Georgoulias V, Easton DF, Pharoah P, Dunning AM, Bishop DT, Neuhausen SL, Steele L, Ashworth A, Closas MG, Houlston R, Swerdlow A, Orr N. *Common susceptibility loci for male breast cancer.* J Natl Cancer Inst. 2021 Apr 6;113(4):453-461. doi: 10.1093/jnci/djaa101.
IF: 13.506
Citations: 3
PRESS/MEDIA RELEASE:
https://uk.news.yahoo.com/researchers-identify-three-genetic-variants-230100897.html?guccounter=1&guce_referrer=aHR0cHM6Ly9veGZvcmRqb3VybmFscy5hbHRtZXRyaWMuY29tL2RldGFpbHMvODgxMzAxNTYvbmV3cw&guce_referrer_sig=AQAAAHGvcu6DtOwo3WuTzM-klW7V2iKqDRR-9t-UhwUQKrDIfVr8jSnypt70ig1ScDbwm-v_41TVTNvhFDfNnms0n7k0pJiKi1YvzCeCxwNBvPKDdnZMfy8CkcLUOoUDD9X0vebMH_ODdXMXKg7lA1_8X2azebshdu6HJY3lexJKRJlX

5. Sanese P, Fasano C, Buscemi G, Bottino C, Corbetta S, Fabini E, **Silvestri V**, Valentini V, Disciglio V, Forte G, Lepore Signorile M, De Marco K, Bertora S, Grossi V, Guven U, Porta N, Di Maio V, Manoni E, Giannelli G, Bartolini M, Del Rio A, Caretti G, Ottini L, Simone C. *Targeting SMYD3 to sensitize homologous recombination-proficient tumors to PARP-mediated synthetic lethality*. iScience. 2020 Oct 7;23(10):101604. doi: 10.1016/j.isci.2020.101604.
IF: 4.447
Citations: 4
PRESS/MEDIA RELEASE:
https://bari.repubblica.it/cronaca/2020/09/24/news/tumori_scoperta_in_puglia_la_proteina_che_ripara_il_dna_delle_cellule_cancerogene_si_potra_evitare_la_chemio_-268390799/

6. **Silvestri V**, Leslie G, Barnes DR; and the CIMBA Group, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Barkardottir RB, Barroso A, Barrowdale D, Benitez J, Bonanni B, Borg A, Buys SS, Caldés T, Caligo MA, Capalbo C, Campbell I, Chung WK, Claes KBM, Colonna SV, Cortesi L, Couch FJ, de la Hoya M, Diez O, Ding YC, Domchek S, Easton DF, Ejlertsen B, Engel C, Evans DG, Feliubadalò L, Foretova L, Fostira F, Géczi L, Gerdes AM, Glendon G, Godwin AK, Goldgar DE, Hahnen E, Hogervorst FBL, Hopper JL, Hulick PJ, Isaacs C, Izquierdo A, James PA, Janavicius R, Jensen UB, John EM, Joseph V, Konstantopoulou I, Kurian AW, Kwong A, Landucci E, Lesueur F, Loud JT, Machackova E, Mai PL, Majidzadeh-A K, Manoukian S, Montagna M, Moserle L, Mulligan AM, Nathanson KL, Nevanlinna H, Ngeow Yuen Ye J, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Osorio A, Papi L, Park SK, Pedersen IS, Perez-Segura P, Petersen AH, Pinto P, Porfirio B, Pujana MA, Radice P, Rantala J, Rashid MU, Rosenzweig B, Rossing M, Santamariña M, Schmutzler RK, Senter L, Simard J, Singer CF, Solano AR, Southey MC, Steele L, Steinsnyder Z, Stoppa-Lyonnet D, Tan YY, Teixeira MR, Teo SH, Terry MB, Thomassen M, Toland AE, Torres-Esquius S, Tung N, van Asperen CJ, Vega A, Viel A, Vierstraete J, Wappenschmidt B, Weitzel JN, Wieme G, Yoon SY, Zorn KK, McGuffog L, Parsons MT, Hamann U, Greene MH, Kirk JA, Neuhausen SL, Rebbeck TR, Tischkowitz M, Chenevix-Trench G, Antoniou AC, Friedman E, Ottini L. *Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).* JAMA Oncol. 2020 Aug 1;6(8):1218-1230. doi: 10.1001/jamaoncol.2020.2134.
IF: 24.799
Citations: 11
PRESS/MEDIA RELEASE:
https://www.uniroma1.it/sites/default/files/field_file_allegati/segnalazione_aggiornata.pdf

7. Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, Dunning AM, Redman J, Scarth J, Plaskocinska I, Luccarini C, Shah M, Pooley K, Dorling L, Lee A, Adank MA, Adlard J, Aittomäki K, Andrulis IL, Ang P, Barwell J, Bernstein JL, Bobolis K, Borg Å, Blomqvist C, Claes KBM, Concannon P, Cuggia A, Culver JO, Damiola F, de Pauw A, Diez O, Dolinsky JS, Domchek SM, Engel C, Evans DG, Fostira F, Garber J, Golmard L, Goode EL, Gruber SB, Hahnen E, Hake C, Heikkinen T, Hurley JE, Janavicius R, Kleibl Z, Kleiblova P, Konstantopoulou I, Kvist A, Laduca H, Lee ASG, Lesueur F, Maher ER, Mannermaa A, Manoukian S, McFarland R, McKinnon W, Meindl A, Metcalfe K, Mohd Taib NA, Moilanen J, Nathanson KL, Neuhausen S, Ng PS, Nguyen-Dumont T, Nielsen SM, Obermair F, Offit K, Olopade OI, Ottini L, Penkert J, Pylkäs K, Radice P, Ramus SJ, Rudaitis V, Side L, Silva-Smith R, **Silvestri V**, Skytte AB, Slavin T, Soukupova J, Tondini C, Trainer AH, Unzeitig G, Usha L, van Overeem Hansen T, Whitworth J, Wood M, Yip CH, Yoon SY, Yussuf A, Zogopoulos G, Goldgar D, Hopper JL, Chenevix-Trench G, Pharoah P, George SHL, Balmaña J, Houdayer C, James P, El-Haffaf Z, Ehrencrona H, Janatova M, Peterlongo P, Nevanlinna H, Schmutzler R, Teo SH, Robson M, Pal T, Couch F, Weitzel JN, Elliott A, Southey M, Winqvist R, Easton DF, Foulkes WD, Antoniou AC, Tischkowitz M. *Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.* J Clin Oncol. 2020 Mar 1;38(7):674-685. doi: 10.1200/JCO.19.01907.
IF: 28.245
Citations: 106
PRESS/MEDIA RELEASE:
https://www.facingourrisk.org/XRAY/PALB2-cancer-risk?utm_source=CURE&utm_medium=website
https://www.curetoday.com/view/a-landmark-study-shows-palb2-mutations-increase-the-risk-of-certain-cancers

8. Patel VL, Busch EL, Friebel TM, Cronin A, Leslie G, McGuffog L, Adlard J, Agata S, Agnarsson BA, Ahmed M, Aittomäki K, Alducci E, Andrulis IL, Arason A, Arnold N, Artioli G, Arver B, Auber B, Azzollini J, Balmaña J, Barkardottir RB, Barnes DR, Barroso A, Barrowdale D, Belotti M, Benitez J, Bertelsen B, Blok MJ, Bodrogi I, Bonadona V, Bonanni B, Bondavalli D, Boonen SE, Borde J, Borg A, Bradbury AR, Brady A, Brewer C, Brunet J, Buecher B, Buys SS, Cabezas-Camarero S, Caldés T, Caliebe A, Caligo MA, Calvello M, Campbell IG, Carnevali I, Carrasco E, Chan TL, Chu ATW, Chung WK, Claes KBM, Collaborators GS, Collaborators E, Cook J, Cortesi L, Couch FJ, Daly MB, Damante G, Darder E, Davidson R, de la Hoya M, Della Puppa L, Dennis J, Díez O, Ding YC, Ditsch N, Domchek SM, Donaldson A, Dworniczak B, Easton DF, Eccles DM, Eeles RA, Ehrencrona H, Ejlertsen B, Engel C, Evans DG, Faivre L, Faust U, Feliubadaló L, Foretova L, Fostira F, Fountzilas G, Frost D, García-Barberán V, Garre P, Gauthier-Villars M, Géczi L, Gehrig A, Gerdes AM, Gesta P, Giannini G, Glendon G, Godwin AK, Goldgar DE, Greene MH, Gutierrez-Barrera AM, Hahnen E, Hamann U, Hauke J, Herold N, Hogervorst FBL, Honisch E, Hopper JL, Hulick PJ, Investigators K, Investigators H, Izatt L, Jager A, James P, Janavicius R, Jensen UB, Jensen TD, Johannsson OT, John EM, Joseph V, Kang E, Kast K, Kiiski JI, Kim SW, Kim Z, Ko KP, Konstantopoulou I, Kramer G, Krogh L, Kruse TA, Kwong A, Larsen M, Lasset C, Lautrup C, Lázaro C, Lee J, Lee JW, Lee MH, Lemke J, Lesueur F, Liljegren A, Lindblom A, Llovet P, Lopez-Fernández A, Lopez-Perolio I, Lorca V, Loud JT, Ma ESK, Mai PL, Manoukian S, Mari V, Martin L, Matricardi L, Mebirouk N, Medici V, Meijers-Heijboer HEJ, Meindl A, Mensenkamp AR, Miller C, Molina Gomes D, Montagna M, Mooij TM, Moserle L, Mouret-Fourme E, Mulligan AM, Nathanson KL, Navratilova M, Nevanlinna H, Niederacher D, Cilius Nielsen FC, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Ong KR, Osorio A, Ott CE, Palli D, Park SK, Parsons MT, Pedersen IS, Peissel B, Peixoto A, Pérez-Segura P, Peterlongo P, Høgh Petersen A, Porteous ME, Pujana MA, Radice P, Ramser J, Rantala J, Rashid MU, Rhiem K, Rizzolo P, Robson ME, Rookus MA, Rossing CM, Ruddy KJ, Santos C, Saule C, Scarpitta R, Schmutzler RK, Schuster H, Senter L, Seynaeve CM, Shah PD, Sharma P, Shin VY, **Silvestri V**, Simard J, Singer CF, Skytte AB, Snape K, Solano AR, Soucy P, Southey MC, Spurdle AB, Steele L, Steinemann D, Stoppa-Lyonnet D, Stradella A, Sunde L, Sutter C, Tan YY, Teixeira MR, Teo SH, Thomassen M, Tibiletti MG, Tischkowitz M, Tognazzo S, Toland AE, Tommasi S, Torres D, Toss A, Trainer AH, Tung N, van Asperen CJ, van der Baan FH, van der Kolk LE, van der Luijt RB, van Hest LP, Varesco L, Varon-Mateeva R, Viel A, Vierstraete J, Villa R, von Wachenfeldt A, Wagner P, Wang-Gohrke S, Wappenschmidt B, Weitzel JN, Wieme G, Yadav S, Yannoukakos D, Yoon SY, Zanzottera C, Zorn KK, D'Amico AV, Freedman ML, Pomerantz MM, Chenevix-Trench G, Antoniou AC, Neuhausen SL, Ottini L, Nielsen HR, Rebbeck TR. *Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.* Cancer Res. 2020 Feb 1;80(3):624-638. doi: 10.1158/0008-5472.CAN-19-1840.
IF: 9.727
Citations: 19

9. Rizzolo P*, **Silvestri V***, Valentini V, Zelli V, Bucalo A, Zanna I, Bianchi S, Tibiletti MG, Russo A, Varesco L, Tedaldi G, Bonanni B, Azzollini J, Manoukian S, Coppa A, Giannini G, Cortesi L, Viel A, Montagna M, Peterlongo P, Radice P, Palli D, Ottini L. *Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk.* Endocr Connect. 2019 Aug;8(8):1224-1229. doi: 10.1530/EC-19-0225. (*co-first authors).
IF: 3.041
Citations: 2

10.Rizzolo P, Zelli V, **Silvestri V**, Valentini V, Zanna I, Bianchi S, Masala G, Spinelli AM, Tibiletti MG, Russo A, Varesco L, Giannini G, Capalbo C, Calistri D, Cortesi L, Viel A, Bonanni B, Azzollini J, Manoukian S, Montagna M, Peterlongo P, Radice P, Palli D, Ottini L. *Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy.* Int J Cancer. 2019 Jul 15;145(2):390-400. doi: 10.1002/ijc.32106.
IF: 4.982
Citations: 23
PRESS/MEDIA RELEASE:
https://www.repubblica.it/dossier/salute/saluteseno/2019/01/28/news/tumore_al_seno_maschile_uno_studio_italiano_individua_i_geni_che_ne_aumentano_il_rischio-217655530/

11.**Silvestri V**, Rizzolo P, Zelli V, Valentini V, Zanna I, Bianchi S, Tibiletti MG, Varesco L, Russo A, Tommasi S, Coppa A, Capalbo C, Calistri D, Viel A, Cortesi L, Manoukian S, Bonanni B, Montagna M, Palli D, Radice P, Peterlongo P, Ottini L. *A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy*. Breast. 2018 Apr; 38:92-97. doi: 10.1016/j.breast.2017.12.013.
IF: 3.494
Citations: 15

12.Lecarpentier J*, **Silvestri V***, Kuchenbaecker KB, Barrowdale D, Dennis J, McGuffog L, Soucy P, Leslie G, Rizzolo P, Navazio AS, Valentini V, Zelli V, Lee A, Amin Al Olama A, Tyrer JP, Southey M, John EM, Conner TA, Goldgar DE, Buys SS, Janavicius R, Steele L, Ding YC, Neuhausen SL, Hansen TVO, Osorio A, Weitzel JN, Toss A, Medici V, Cortesi L, Zanna I, Palli D, Radice P, Manoukian S, Peissel B, Azzollini J, Viel A, Cini G, Damante G, Tommasi S, Peterlongo P, Fostira F, Hamann U, Evans DG, Henderson A, Brewer C, Eccles D, Cook J, Ong KR, Walker L, Side LE, Porteous ME, Davidson R, Hodgson S, Frost D, Adlard J, Izatt L, Eeles R, Ellis S, Tischkowitz M; EMBRACE, Godwin AK, Meindl A, Gehrig A, Dworniczak B, Sutter C, Engel C, Niederacher D, Steinemann D, Hahnen E, Hauke J, Rhiem K, Kast K, Arnold N, Ditsch N, Wang-Gohrke S, Wappenschmidt B, Wand D, Lasset C, Stoppa-Lyonnet D, Belotti M, Damiola F, Barjhoux L, Mazoyer S; GEMO Study Collaborators, Van Heetvelde M, Poppe B, De Leeneer K, Claes KBM, de la Hoya M, Garcia-Barberan V, Caldes T, Perez Segura P, Kiiski JI, Aittomäki K, Khan S, Nevanlinna H, van Asperen CJ; HEBON, Vaszko T, Kasler M, Olah E, Balmaña J, Gutiérrez-Enríquez S, Diez O, Teulé A, Izquierdo A, Darder E, Brunet J, Del Valle J, Feliubadalo L, Pujana MA, Lazaro C, Arason A, Agnarsson BA, Johannsson OT, Barkardottir RB, Alducci E, Tognazzo S, Montagna M, Teixeira MR, Pinto P, Spurdle AB, Holland H; KConFab Investigators, Lee JW, Lee MH, Lee J, Kim SW, Kang E, Kim Z, Sharma P, Rebbeck TR, Vijai J, Robson M, Lincoln A, Musinsky J, Gaddam P, Tan YY, Berger A, Singer CF, Loud JT, Greene MH, Mulligan AM, Glendon G, Andrulis IL, Toland AE, Senter L, Bojesen A, Nielsen HR, Skytte AB, Sunde L, Jensen UB, Pedersen IS, Krogh L, Kruse TA, Caligo MA, Yoon SY, Teo SH, von Wachenfeldt A, Huo D, Nielsen SM, Olopade OI, Nathanson KL, Domchek SM, Lorenchick C, Jankowitz RC, Campbell I, James P, Mitchell G, Orr N, Park SK, Thomassen M, Offit K, Couch FJ, Simard J, Easton DF, Chenevix-Trench G, Schmutzler RK, Antoniou AC, Ottini L. *Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.* J Clin Oncol. 2017 Jul 10;35(20):2240-2250. doi: 10.1200/JCO.2016.69.4935. (*co-first authors).
IF: 26.303
Citations: 91
PRESS/MEDIA RELEASE:
https://www.uniroma1.it/sites/default/files/field_file_allegati/segnalazione_dei_media_okbs.pdf
https://asco.altmetric.com/details/19662407/news
ACCOMPANYING EDITORIAL: Kraft P. Fine Tuning the Risk of Hereditary Cancer Using Genome-Wide Association Studies. J Clin Oncol. 2017 Jul 10;35(20):2224-2225. doi: 10.1200/JCO.2017.72.8071.

13.**Silvestri V**, Zelli V, Valentini V, Rizzolo P, Navazio AS, Coppa A, Agata S, Oliani C, Barana D, Castrignanò T, Viel A, Russo A, Tibiletti MG, Zanna I, Masala G, Cortesi L, Manoukian S, Azzollini J, Peissel B, Bonanni B, Peterlongo P, Radice P, Palli D, Giannini G, Chillemi G, Montagna M, Ottini L. *Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene.* Cancer. 2017 Jan 1;123(2):210-218. doi: 10.1002/cncr.30337.
IF: 6.537
Citations: 20
PRESS/MEDIA RELEASE:
https://www.corriere.it/salute/sportello_cancro/18_maggio_11/anche-maschi-possono-ereditare-cancro-seno-scoperti-nuovi-geni-ae8d14c4-5501-11e8-a20f-03aeddc0ac78.shtml

14.Chandramouli B, **Silvestri V**, Scarno M, Ottini L, Chillemi G. *Smyd3 open & closed lock mechanism for substrate recruitment: The hinge motion of C-terminal domain inferred from μ-second molecular dynamics simulations.* Biochim Biophys Acta. 2016 Jul;1860(7):1466-74. doi: 10.1016/j.bbagen.2016.04.006.
IF: 4.702
Citations: 11

15.**Silvestri V**, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY, Mitchell G, James P, Thull DL, Zorn KK, Carter NJ, Nathanson KL, Domchek SM, Rebbeck TR, Ramus SJ, Nussbaum RL, Olopade OI, Rantala J, Yoon SY, Caligo MA, Spugnesi L, Bojesen A, Pedersen IS, Thomassen M, Jensen UB, Toland AE, Senter L, Andrulis IL, Glendon G, Hulick PJ, Imyanitov EN, Greene MH, Mai PL, Singer CF, Rappaport-Fuerhauser C, Kramer G, Vijai J, Offit K, Robson M, Lincoln A, Jacobs L, Machackova E, Foretova L, Navratilova M, Vasickova P, Couch FJ, Hallberg E, Ruddy KJ, Sharma P, Kim SW; kConFab Investigators, Teixeira MR, Pinto P, Montagna M, Matricardi L, Arason A, Johannsson OT, Barkardottir RB, Jakubowska A, Lubinski J, Izquierdo A, Pujana MA, Balmaña J, Diez O, Ivady G, Papp J, Olah E, Kwong A; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), Nevanlinna H, Aittomäki K, Perez Segura P, Caldes T, Van Maerken T, Poppe B, Claes KB, Isaacs C, Elan C, Lasset C, Stoppa-Lyonnet D, Barjhoux L, Belotti M, Meindl A, Gehrig A, Sutter C, Engel C, Niederacher D, Steinemann D, Hahnen E, Kast K, Arnold N, Varon-Mateeva R, Wand D, Godwin AK, Evans DG, Frost D, Perkins J, Adlard J, Izatt L, Platte R, Eeles R, Ellis S; EMBRACE, Hamann U, Garber J, Fostira F, Fountzilas G, Pasini B, Giannini G, Rizzolo P, Russo A, Cortesi L, Papi L, Varesco L, Palli D, Zanna I, Savarese A, Radice P, Manoukian S, Peissel B, Barile M, Bonanni B, Viel A, Pensotti V, Tommasi S, Peterlongo P, Weitzel JN, Osorio A, Benitez J, McGuffog L, Healey S, Gerdes AM, Ejlertsen B, Hansen TV, Steele L, Ding YC, Tung N, Janavicius R, Goldgar DE, Buys SS, Daly MB, Bane A,Terry MB, John EM, Southey M, Easton DF, Chenevix-Trench G, Antoniou AC, Ottini L. *Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.* Breast Cancer Res. 2016 Feb 9;18(1):15. doi: 10.1186/s13058-016-0671-y.
IF: 6.345
Citations: 57
PRESS/MEDIA RELEASE:
http://blogs.biomedcentral.com/on-medicine/2016/02/10/new-insights-role-gender-breast-cancer-development/

16.**Silvestri V**, Rizzolo P, Scarnò M, Chillemi G, Navazio AS, Valentini V, Zelli V, Zanna I, Saieva C, Masala G, Bianchi S, Manoukian S, Barile M, Pensotti V, Peterlongo P, Varesco L, Tommasi S, Russo A, Giannini G, Cortesi L, Viel A, Montagna M, Radice P, Palli D, Ottini L. *Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: results from a multicenter study in Italy*. Eur J Cancer. 2015 Nov;51(16):2289-95. doi: 10.1016/j.ejca.2015.07.020.
IF: 6.163
Citations: 20

17.Peterlongo P, Catucci I, Colombo M, Caleca L, Mucaki E, Bogliolo M, Marin M, Damiola F, Bernard L, Pensotti V, Volorio S, Dall'Olio V, Meindl A, Bartram C, Sutter C, Surowy H, Sornin V, Dondon MG, Eon-Marchais S, Stoppa-Lyonnet D, Andrieu N, Sinilnikova OM; GENESIS, Mitchell G, James PA, Thompson E; kConFab; SWE-BRCA, Marchetti M, Verzeroli C, Tartari C, Capone GL, Putignano AL, Genuardi M, Medici V, Marchi I, Federico M, Tognazzo S, Matricardi L, Agata S, Dolcetti R, Della Puppa L, Cini G, Gismondi V, Viassolo V, Perfumo C, Mencarelli MA, Baldassarri M, Peissel B, Roversi G, **Silvestri V**, Rizzolo P, Spina F, Vivanet C, Tibiletti MG, Caligo MA, Gambino G, Tommasi S, Pilato B, Tondini C, Corna C, Bonanni B, Barile M, Osorio A, Benitez J, Balestrino L, Ottini L, Manoukian S, Pierotti MA, Renieri A, Varesco L, Couch FJ, Wang X, Devilee P, Hilbers FS, van Asperen CJ, Viel A, Montagna M, Cortesi L, Diez O, Balmaña J, Hauke J, Schmutzler RK, Papi L, Pujana MA, Lázaro C, Falanga A, Offit K, Vijai J, Campbell I, Burwinkel B, Kvist A, Ehrencrona H, Mazoyer S, Pizzamiglio S, Verderio P, Surralles J, Rogan PK, Radice P. *FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor.* Hum Mol Genet. 2015 Sep 15;24(18):5345-55. doi: 10.1093/hmg/ddv251.
IF: 5.985
Citations: 60
PRESS/MEDIA RELEASE:
https://www.benessereblog.it/tumore-al-seno-scoperta-nuova-mutazione-che-aumenta-il-rischio

18.Rizzolo P*, **Silvestri V***, Tommasi S, Pinto R, Danza K, Falchetti M, Gulino M, Frati P, Ottini L. *Male breast cancer: genetics, epigenetics, and ethical aspects*. Ann Oncol. 2013 Nov;24 Suppl 8: viii75-viii82. doi: 10.1093/annonc/mdt316. (*co-first authors).

IF: 6.578
Citations: 62

Part X – All Publications

1. Li S*, **Silvestri V***, Leslie G, Rebbeck TR, Neuhausen SL, Hopper JL, Nielsen HR, Lee A, Yang X, McGuffog L, Parsons MT, Andrulis IL, Arnold N, Belotti M, Borg Å, Buecher B, Buys SS, Caputo SM, Chung WK, Colas C, Colonna SV, Cook J, Daly MB, de la Hoya M, de Pauw A, Delhomelle H, Eason J, Engel C, Evans DG, Faust U, Fehm TN, Fostira F, Fountzilas G, Frone M, Garcia-Barberan V, Garre P, Gauthier-Villars M, Gehrig A, Glendon G, Goldgar DE, Golmard L, Greene MH, Hahnen E, Hamann U, Hanson H, Hassan T, Hentschel J, Horvath J, Izatt L, Janavicius R, Jiao Y, John EM, Karlan BY, Kim SW, Konstantopoulou I, Kwong A, Laugé A, Lee JW, Lesueur F, Mebirouk N, Meindl A, Mouret-Fourme E, Musgrave H, Ngeow Yuen Yie J, Niederacher D, Park SK, Pedersen IS, Ramser J, Ramus SJ, Rantala J, Rashid MU, Reichl F, Ritter J, Rump A, Santamariña M, Saule C, Schmidt G, Schmutzler RK, Senter L, Shariff S, Singer CF, Southey MC, Stoppa-Lyonnet D, Sutter C, Tan Y, Teo SH, Terry MB, Thomassen M, Tischkowitz M, Toland AE, Torres D, Vega A, Wagner SA, Wang-Gohrke S, Wappenschmidt B, Weber BHF, Yannoukakos D, Spurdle AB, Easton DF, Chenevix-Trench G, Ottini L, Antoniou AC. *Cancer Risks Associated with BRCA1 and BRCA2 Pathogenic Variants.* J Clin Oncol. 2022 Jan 25:JCO2102112. doi: 10.1200/JCO.21.02112 (*co-first authors). IF: 44.544.

2. Watanabe M, Risi R, Tafuri MA, **Silvestri V**, D'Andrea D, Raimondo D, Rea S, Di Vincenzo F, Profico A, Tuccinardi D, Sciuto R, Basciani S, Mariani S, Lubrano C, Cinti S, Ottini L, Manzi G, Gnessi L. *Bone density and genomic analysis unfold cold adaptation mechanisms of ancient inhabitants of Tierra del Fuego.* Sci Rep. 2021 Dec 2;11(1):23290. doi: 10.1038/s41598-021-02783-1. IF: 4.379.

3. Barnes DR*, **Silvestri V***, Leslie G, McGuffog L, Dennis J, Yang X, Adlard J, Agnarsson BA, Ahmed M, Aittomäki K, Andrulis IL, Arason A, Arnold N, Auber B, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Barwell J, Belotti M, Benitez J, Berthet P, Boonen SE, Borg Å, Bozsik A, Brady A, Brennan P, Brewer C, Brunet J, Bucalo A, Buys SS, Caldés T, Caligo MA, Campbell I, Cassingham H, Lotte Christensen L, Cini G, Claes KBM; GEMO Study Collaborators; EMBRACE Collaborators, Cook J, Coppa A, Cortesi L, Damante G, Darder E, Davidson R, de la Hoya M, De Leeneer K, de Putter R, Del Valle J, Diez O, Chun Ding Y, Domchek SM, Donaldson A, Eason J, Eeles R, Engel C, Gareth Evans D, Feliubadaló L, Fostira F, Frone M, Frost D, Gallagher D, Gehrig A, Giraud S, Glendon G, Godwin AK, Goldgar DE, Greene MH, Gregory H, Gross E, Hahnen E, Hamann U, Hansen TVO, Hanson H, Hentschel J, Horvath J; KConFab Investigators; HEBON Investigators, Izatt L, Izquierdo A, James PA, Janavicius R, Birk Jensen U, Johannsson OT, John EM, Kramer G, Kroeldrup L, Kruse TA, Lautrup C, Lazaro C, Lesueur F, Lopez-Fernández A, Mai PL, Manoukian S, Matrai Z, Matricardi L, Maxwell KN, Mebirouk N, Meindl A, Montagna M, Monteiro AN, Morrison PJ, Muranen TA, Murray A, Nathanson KL, Neuhausen SL, Nevanlinna H, Nguyen-Dumont T, Niederacher D, Olah E, Olopade OI, Palli D, Parsons MT, Sokilde Pedersen I, Peissel B, Perez-Segura P, Peterlongo P, Petersen AH, Pinto P, Porteous ME, Pottinger C, Angel Pujana M, Radice P, Ramser J, Rantala J, Robson M, Rogers MT, Rønlund K, Rump A, María Sánchez de Abajo A, Shah PD, Sharif S, Side LE, Singer CF, Stadler Z, Steele L, Stoppa-Lyonnet D, Sutter C, Yen Tan Y, Teixeira MR, Teulé A, Thull DL, Tischkowitz M, Toland AE, Tommasi S, Toss A, Trainer AH, Tripathi V, Valentini V, van Asperen CJ, Venturelli M, Viel A, Vijai J, Walker L, Wang-Gohrke S, Wappenschmidt B, Whaite A, Zanna I, Offit K, Thomassen M, Couch FJ, Schmutzler RK, Simard J, Easton DF, Chenevix-Trench G, Antoniou AC, Ottini L; Consortium of Investigators of Modifiers of BRCA1 and BRCA2. *Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.* J Natl Cancer Inst. 2021 Jul 28:djab147. doi: 10.1093/jnci/djab147. IF: 13.506. (*co-first authors).

4. Zelli V, **Silvestri V**, Valentini V, Bucalo A, Rizzolo P, Zanna I, Bianchi S, Coppa A, Giannini G, Cortesi L, Calistri D, Tibiletti MG, Fox SB, kConFab, Palli D, Ottini L. *Transcriptome of male breast cancer matched with germline profiling reveals novel molecular subtypes with possible clinical relevance.* Cancers (Basel). 2021 Sep 8;13(18):4515. doi: 10.3390/cancers13184515. IF: 6.639.

5. Caini S, Fiorito G, Palli D, Bendinelli B, Polidoro S, **Silvestri V**, Ottini L, Ambrogetti D, Zanna I, Saieva C, Masala G. *Pre-diagnostic DNA methylation patterns differ according to mammographic breast density amongst women who subsequently develop breast cancer: a case-only study in the EPIC-Florence cohort.* Breast Cancer Res Treat. 2021 Jun 8. doi: 10.1007/s10549-021-06273-w. IF: 4.872.

6. Maguire S, Perraki E, Tomczyk K, Jones ME, Fletcher O, Pugh M, Winter T, Thompson K, Cooke R; kConFab Consortium, Trainer A, James P, Bojesen S, Flyger H, Nevanlinna H, Mattson J, Friedman E, Laitman Y, Palli D, Masala G, Zanna I, Ottini L, **Silvestri V**, Hollestelle A, Hooning MJ, Novaković S, Krajc M, Gago-Dominguez M, Castelao JE, Olsson H, Hedenfalk I, Saloustros E, Georgoulias V, Easton DF, Pharoah P, Dunning AM, Bishop DT, Neuhausen SL, Steele L, Ashworth A, Closas MG, Houlston R, Swerdlow A, Orr N. *Common susceptibility loci for male breast cancer*. J Natl Cancer Inst. 2021 Apr 6;113(4):453-461. doi: 10.1093/jnci/djaa101. IF: 13.506.

7. Valentini V, **Silvestri V,** Marraffa F, Greco G, Bucalo A, Grassi S, Gagliardi A, Mazzotta A, Ottini L, Richetta AG. *Gut microbiome profile in psoriatic patients treated and untreated with biologic therapy.* J Dermatol. 2021 Jan 28. doi: 10.1111/1346-8138.15680. IF: 4.005.

8. Bucalo A, Rega F, Zangrilli A, **Silvestri V**, Valentini V, Scafetta G, Marraffa F, Grassi S, Rogante E, Piccolo A, Cucchiara S, Viola F, Bianchi L, Ottini L, Richetta A. *Paradoxical Psoriasis Induced by Anti-TNFα Treatment: Evaluation of Disease-Specific Clinical and Genetic Markers.* Int J Mol Sci. 2020 Oct 23;21(21):7873. doi: 10.3390/ijms21217873. IF: 4.556.

9. Sanese P, Fasano C, Buscemi G, Bottino C, Corbetta S, Fabini E, **Silvestri V**, Valentini V, Disciglio V, Forte G, Lepore Signorile M, De Marco K, Bertora S, Grossi V, Guven U, Porta N, Di Maio V, Manoni E, Giannelli G, Bartolini M, Del Rio A, Caretti G, Ottini L, Simone C. *Targeting SMYD3 to sensitize homologous recombination-proficient tumors to PARP-mediated synthetic lethality.* iScience. 2020 Oct 7;23(10):101604. doi: 10.1016/j.isci.2020.101604. IF: 4.447.

10. **Silvestri V**, Leslie G, Barnes DR; and the CIMBA Group, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Barkardottir RB, Barroso A, Barrowdale D, Benitez J, Bonanni B, Borg A, Buys SS, Caldés T, Caligo MA, Capalbo C, Campbell I, Chung WK, Claes KBM, Colonna SV, Cortesi L, Couch FJ, de la Hoya M, Diez O, Ding YC, Domchek S, Easton DF, Ejlertsen B, Engel C, Evans DG, Feliubadalò L, Foretova L, Fostira F, Géczi L, Gerdes AM, Glendon G, Godwin AK, Goldgar DE, Hahnen E, Hogervorst FBL, Hopper JL, Hulick PJ, Isaacs C, Izquierdo A, James PA, Janavicius R, Jensen UB, John EM, Joseph V, Konstantopoulou I, Kurian AW, Kwong A, Landucci E, Lesueur F, Loud JT, Machackova E, Mai PL, Majidzadeh-A K, Manoukian S, Montagna M, Moserle L, Mulligan AM, Nathanson KL, Nevanlinna H, Ngeow Yuen Ye J, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Osorio A, Papi L, Park SK, Pedersen IS, Perez-Segura P, Petersen AH, Pinto P, Porfirio B, Pujana MA, Radice P, Rantala J, Rashid MU, Rosenzweig B, Rossing M, Santamariña M, Schmutzler RK, Senter L, Simard J, Singer CF, Solano AR, Southey MC, Steele L, Steinsnyder Z, Stoppa-Lyonnet D, Tan YY, Teixeira MR, Teo SH, Terry MB, Thomassen M, Toland AE, Torres-Esquius S, Tung N, van Asperen CJ, Vega A, Viel A, Vierstraete J, Wappenschmidt B, Weitzel JN, Wieme G, Yoon SY, Zorn KK, McGuffog L, Parsons MT, Hamann U, Greene MH, Kirk JA, Neuhausen SL, Rebbeck TR, Tischkowitz M, Chenevix-Trench G, Antoniou AC, Friedman E, Ottini L. *Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).* JAMA Oncol. 2020 Aug 1;6(8):1218-1230. doi: 10.1001/jamaoncol.2020.2134. IF: 24.799.

11. Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, Dunning AM, Redman J, Scarth J, Plaskocinska I, Luccarini C, Shah M, Pooley K, Dorling L, Lee A, Adank MA, Adlard J, Aittomäki K, Andrulis IL, Ang P, Barwell J, Bernstein JL, Bobolis K, Borg Å, Blomqvist C, Claes KBM, Concannon P, Cuggia A, Culver JO, Damiola F, de Pauw A, Diez O, Dolinsky JS, Domchek SM, Engel C, Evans DG, Fostira F, Garber J, Golmard L, Goode EL, Gruber SB, Hahnen E, Hake C, Heikkinen T, Hurley JE, Janavicius R, Kleibl Z, Kleiblova P, Konstantopoulou I, Kvist A, Laduca H, Lee ASG, Lesueur F, Maher ER, Mannermaa A, Manoukian S, McFarland R, McKinnon W, Meindl A, Metcalfe K, Mohd Taib NA, Moilanen J, Nathanson KL, Neuhausen S, Ng PS, Nguyen-Dumont T, Nielsen SM, Obermair F, Offit K, Olopade OI, Ottini L, Penkert J, Pylkäs K, Radice P, Ramus SJ, Rudaitis V, Side L, Silva-Smith R, **Silvestri V**, Skytte AB, Slavin T, Soukupova J, Tondini C, Trainer AH, Unzeitig G, Usha L, van Overeem Hansen T, Whitworth J, Wood M, Yip CH, Yoon SY, Yussuf A, Zogopoulos G, Goldgar D, Hopper JL, Chenevix-Trench G, Pharoah P, George SHL, Balmaña J, Houdayer C, James P, El-Haffaf Z, Ehrencrona H, Janatova

M, Peterlongo P, Nevanlinna H, Schmutzler R, Teo SH, Robson M, Pal T, Couch F, Weitzel JN, Elliott A, Southey M, Winqvist R, Easton DF, Foulkes WD, Antoniou AC, Tischkowitz M. *Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.* J Clin Oncol. 2020 Mar 1;38(7):674-685. doi: 10.1200/JCO.19.01907. IF: 28.245.

12. Patel VL, Busch EL, Friebel TM, Cronin A, Leslie G, McGuffog L, Adlard J, Agata S, Agnarsson BA, Ahmed M, Aittomäki K, Alducci E, Andrulis IL, Arason A, Arnold N, Artioli G, Arver B, Auber B, Azzollini J, Balmaña J, Barkardottir RB, Barnes DR, Barroso A, Barrowdale D, Belotti M, Benitez J, Bertelsen B, Blok MJ, Bodrogi I, Bonadona V, Bonanni B, Bondavalli D, Boonen SE, Borde J, Borg A, Bradbury AR, Brady A, Brewer C, Brunet J, Buecher B, Buys SS, Cabezas-Camarero S, Caldés T, Caliebe A, Caligo MA, Calvello M, Campbell IG, Carnevali I, Carrasco E, Chan TL, Chu ATW, Chung WK, Claes KBM, Collaborators GS, Collaborators E, Cook J, Cortesi L, Couch FJ, Daly MB, Damante G, Darder E, Davidson R, de la Hoya M, Della Puppa L, Dennis J, Díez O, Ding YC, Ditsch N, Domchek SM, Donaldson A, Dworniczak B, Easton DF, Eccles DM, Eeles RA, Ehrencrona H, Ejlertsen B, Engel C, Evans DG, Faivre L, Faust U, Feliubadaló L, Foretova L, Fostira F, Fountzilas G, Frost D, García-Barberán V, Garre P, Gauthier-Villars M, Géczi L, Gehrig A, Gerdes AM, Gesta P, Giannini G, Glendon G, Godwin AK, Goldgar DE, Greene MH, Gutierrez-Barrera AM, Hahnen E, Hamann U, Hauke J, Herold N, Hogervorst FBL, Honisch E, Hopper JL, Hulick PJ, Investigators K, Investigators H, Izatt L, Jager A, James P, Janavicius R, Jensen UB, Jensen TD, Johannsson OT, John EM, Joseph V, Kang E, Kast K, Kiiski JI, Kim SW, Kim Z, Ko KP, Konstantopoulou I, Kramer G, Krogh L, Kruse TA, Kwong A, Larsen M, Lasset C, Lautrup C, Lázaro C, Lee J, Lee JW, Lee MH, Lemke J, Lesueur F, Liljegren A, Lindblom A, Llovet P, Lopez-Fernández A, Lopez-Perolio I, Lorca V, Loud JT, Ma ESK, Mai PL, Manoukian S, Mari V, Martin L, Matricardi L, Mebirouk N, Medici V, Meijers-Heijboer HEJ, Meindl A, Mensenkamp AR, Miller C, Molina Gomes D, Montagna M, Mooij TM, Moserle L, Mouret-Fourme E, Mulligan AM, Nathanson KL, Navratilova M, Nevanlinna H, Niederacher D, Cilius Nielsen FC, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Ong KR, Osorio A, Ott CE, Palli D, Park SK, Parsons MT, Pedersen IS, Peissel B, Peixoto A, Pérez-Segura P, Peterlongo P, Høgh Petersen A, Porteous ME, Pujana MA, Radice P, Ramser J, Rantala J, Rashid MU, Rhiem K, Rizzolo P, Robson ME, Rookus MA, Rossing CM, Ruddy KJ, Santos C, Saule C, Scarpitta R, Schmutzler RK, Schuster H, Senter L, Seynaeve CM, Shah PD, Sharma P, Shin VY, **Silvestri V**, Simard J, Singer CF, Skytte AB, Snape K, Solano AR, Soucy P, Southey MC, Spurdle AB, Steele L, Steinemann D, Stoppa-Lyonnet D, Stradella A, Sunde L, Sutter C, Tan YY, Teixeira MR, Teo SH, Thomassen M, Tibiletti MG, Tischkowitz M, Tognazzo S, Toland AE, Tommasi S, Torres D, Toss A, Trainer AH, Tung N, van Asperen CJ, van der Baan FH, van der Kolk LE, van der Luijt RB, van Hest LP, Varesco L, Varon-Mateeva R, Viel A, Vierstraete J, Villa R, von Wachenfeldt A, Wagner P, Wang-Gohrke S, Wappenschmidt B, Weitzel JN, Wieme G, Yadav S, Yannoukakos D, Yoon SY, Zanzottera C, Zorn KK, D'Amico AV, Freedman ML, Pomerantz MM, Chenevix-Trench G, Antoniou AC, Neuhausen SL, Ottini L, Nielsen HR, Rebbeck TR. *Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness*. Cancer Res. 2020 Feb 1;80(3):624-638. doi: 10.1158/0008-5472.CAN-19-1840. IF: 9.727.

13. Nicolussi A, Belardinilli F, **Silvestri V**, Mahdavian Y, Valentini V, D'Inzeo S, Petroni M, Zani M, Ferraro S, Di Giulio S, Fabretti F, Fratini B, Gradilone A, Ottini L, Giannini G, Coppa A, Capalbo C. *Identification of novel BRCA1 large genomic rearrangements by a computational algorithm of amplicon-based Next-Generation Sequencing data*. PeerJ. 2019 Nov 15;7:e7972. doi: 10.7717/peerj.7972. IF: 2.353.

14. Rizzolo P*, **Silvestri V***, Valentini V, Zelli V, Bucalo A, Zanna I, Bianchi S, Tibiletti MG, Russo A, Varesco L, Tedaldi G, Bonanni B, Azzollini J, Manoukian S, Coppa A, Giannini G, Cortesi L, Viel A, Montagna M, Peterlongo P, Radice P, Palli D, Ottini L. *Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk*. Endocr Connect. 2019 Jul 1. pii: EC-19-0225.R1. doi: 10.1530/EC-19-0225. IF: 3.041 (*co-first authors).

15. Valentini V, Zelli V, Gaggiano E, **Silvestri V**, Rizzolo P, Bucalo A, Calvieri S, Grassi S, Frascione P, Donati P, Soda G, Ottini L, Richetta AG. *MiRNAs as Potential Prognostic Biomarkers for Metastasis in Thin and Thick Primary Cutaneous Melanomas*. Anticancer Res. 2019 Aug;39(8):4085-4093. doi: 10.21873/anticanres.13566. IF: 1.935.

16.Rizzolo P, Zelli V, **Silvestri V**, Valentini V, Zanna I, Bianchi S, Masala G, Spinelli AM, Tibiletti MG, Russo A, Varesco L, Giannini G, Capalbo C, Calistri D, Cortesi L, Viel A, Bonanni B, Azzollini J, Manoukian S, Montagna M, Peterlongo P, Radice P, Palli D, Ottini L. *Insight into genetic susceptibility to*

male breast cancer by multigene panel testing: Results from a multicenter study in Italy. Int J Cancer. 2019 Jul 15;145(2):390-400. doi: 10.1002/ijc.32106. IF: 4.982.

17.Rizzolo P, **Silvestri V**, Bucalo A, Zelli V, Valentini V, Catucci I, Zanna I, Masala G, Bianchi S, Spinelli AM, Tommasi S, Tibiletti MG, Russo A, Varesco L, Coppa A, Calistri D, Cortesi L, Viel A, Bonanni B, Azzollini J, Manoukian S, Montagna M, Radice P, Palli D, Peterlongo P, Ottini L. *Contribution of MUTYH Variants to Male Breast Cancer Risk: Results From a Multicenter Study in Italy*. Front Oncol. 2018 Dec 4; 8:583. doi: 10.3389/fonc.2018.00583. IF: 4.416.

18.Richetta AG, Valentini V, Marraffa F, Paolino G, Rizzolo P, **Silvestri V**, Zelli V, Carbone A, Di Mattia C, Calvieri S, Frascione P, Donati P, Ottini L. *Metastases risk in thin cutaneous melanoma: prognostic value of clinical-pathologic characteristics and mutation profile*. Oncotarget. 2018 Aug 14;9(63):32173-32181. doi: 10.18632/oncotarget.25864.

19.Valentini V, Zelli V, Rizzolo P, **Silvestri V**, Alimandi M, D'Aloia MM, Giustini S, Calvieri S, Richetta AG, Monteleone G, Ottini L. *PIK3CA c.3140A>G mutation in a patient with suspected Proteus Syndrome: a case report*. Clin Case Rep. 2018 Jun 2;6(7):1358-1363. doi: 10.1002/ccr3.1546.

20.Rizzolo P, **Silvestri V**, Valentini V, Zelli V, Zanna I, Masala G, Bianchi S, Palli D, Ottini L. *Gene-specific methylation profiles in BRCA-mutation positive and BRCA-mutation negative male breast cancers*. Oncotarget. 2018 Apr 13;9(28):19783-19792. doi: 10.18632/oncotarget.24856.

21.Zanna I, **Silvestri V**, Palli D, Magrini A, Rizzolo P, Saieva C, Zelli V, Bendinelli B, Vezzosi V, Valentini V, Bianchi S, Ottini L, Masala G. *Smoking and FGFR2 rs2981582 variant independently modulate male breast cancer survival: A population-based study in Tuscany, Italy*. Breast. 2018 Aug; 40:85-91. doi: 10.1016/j.breast.2018.04.017. IF: 3.494.

22.**Silvestri V**, Rizzolo P, Zelli V, Valentini V, Zanna I, Bianchi S, Tibiletti MG, Varesco L, Russo A, Tommasi S, Coppa A, Capalbo C, Calistri D, Viel A, Cortesi L, Manoukian S, Bonanni B, Montagna M, Palli D, Radice P, Peterlongo P, Ottini L. *A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy*. Breast. 2018 Apr; 38:92-97. doi: 10.1016/j.breast.2017.12.013. IF: 3.494.

23.Neuhausen SL, Shani H, Boker LK, Steele L, Silverman BG, Ottini L, **Silvestri V**, Laitman Y, Korach J, Perri T, Friedman E. *Primary Peritoneal Serous Carcinoma in Men: A Rare and Non-BRCA-associated Entity*. Anticancer Res. 2017 Jun;37(6):3069-3072. IF: 1.865.

24.Lecarpentier J*, **Silvestri V***, Kuchenbaecker KB, Barrowdale D, Dennis J, McGuffog L, Soucy P, Leslie G, Rizzolo P, Navazio AS, Valentini V, Zelli V, Lee A, Amin Al Olama A, Tyrer JP, Southey M, John EM, Conner TA, Goldgar DE, Buys SS, Janavicius R, Steele L, Ding YC, Neuhausen SL, Hansen TVO, Osorio A, Weitzel JN, Toss A, Medici V, Cortesi L, Zanna I, Palli D, Radice P, Manoukian S, Peissel B, Azzollini J, Viel A, Cini G, Damante G, Tommasi S, Peterlongo P, Fostira F, Hamann U, Evans DG, Henderson A, Brewer C, Eccles D, Cook J, Ong KR, Walker L, Side LE, Porteous ME, Davidson R, Hodgson S, Frost D, Adlard J, Izatt L, Eeles R, Ellis S, Tischkowitz M; EMBRACE, Godwin AK, Meindl A, Gehrig A, Dworniczak B, Sutter C, Engel C, Niederacher D, Steinemann D, Hahnen E, Hauke J, Rhiem K, Kast K, Arnold N, Ditsch N, Wang-Gohrke S, Wappenschmidt B, Wand D, Lasset C, Stoppa-Lyonnet D, Belotti M, Damiola F, Barjhoux L, Mazoyer S; GEMO Study Collaborators, Van Heetvelde M, Poppe B, De Leeneer K, Claes KBM, de la Hoya M, Garcia-Barberan V, Caldes T, Perez Segura P, Kiiski JI, Aittomäki K, Khan S, Nevanlinna H, van Asperen CJ; HEBON, Vaszko T, Kasler M, Olah E, Balmaña J, Gutiérrez-Enríquez S, Diez O, Teulé A, Izquierdo A, Darder E, Brunet J, Del Valle J, Feliubadalo L, Pujana MA, Lazaro C, Arason A, Agnarsson BA, Johannsson OT, Barkardottir RB, Alducci E, Tognazzo S, Montagna M, Teixeira MR, Pinto P, Spurdle AB, Holland H; KConFab Investigators, Lee JW, Lee MH, Lee J, Kim SW, Kang E, Kim Z, Sharma P, Rebbeck TR, Vijai J, Robson M, Lincoln A, Musinsky J, Gaddam P, Tan YY, Berger A, Singer CF, Loud JT, Greene MH, Mulligan AM, Glendon G, Andrulis IL, Toland AE, Senter L, Bojesen A, Nielsen HR, Skytte AB, Sunde L, Jensen UB, Pedersen IS, Krogh L, Kruse TA, Caligo MA, Yoon SY, Teo SH, von Wachenfeldt A, Huo D, Nielsen SM, Olopade OI, Nathanson KL, Domchek SM, Lorenchick C, Jankowitz RC, Campbell I, James P, Mitchell G, Orr N, Park SK, Thomassen M, Offit K, Couch FJ, Simard J, Easton DF, Chenevix-Trench G, Schmutzler RK, Antoniou AC, Ottini L. *Prediction of Breast and*

Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J Clin Oncol. 2017 Jul 10;35(20):2240-2250. doi: 10.1200/JCO.2016.69.4935. IF: 26.303 (*co-first authors).

25.Rizzolo P, **Silvestri V**, Ottini L. *Retesting BRCA1/BRCA2 mutation negative male breast cancer patients using next generation sequencing technologies*. Breast Cancer Res Treat. 2017 Feb;162(1):199-200. doi: 10.1007/s10549-017-4108-9. IF: 3.605.

26.Rizzolo P, Navazio AS, **Silvestri V**, Valentini V, Zelli V, Zanna I, Masala G, Bianchi S, Scarnò M, Tommasi S, Palli D, Ottini L. *Somatic alterations of targetable oncogenes are frequently observed in BRCA1/2 mutation negative male breast cancers*. Oncotarget. 2016 Nov 8;7(45):74097-74106. doi: 10.18632/oncotarget.12272. IF: 5.168.

27.**Silvestri V**, Zelli V, Valentini V, Rizzolo P, Navazio AS, Coppa A, Agata S, Oliani C, Barana D, Castrignanò T, Viel A, Russo A, Tibiletti MG, Zanna I, Masala G, Cortesi L, Manoukian S, Azzollini J, Peissel B, Bonanni B, Peterlongo P, Radice P, Palli D, Giannini G, Chillemi G, Montagna M, Ottini L. *Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene*. Cancer. 2017 Jan 1;123(2):210-218. doi: 10.1002/cncr.30337. IF: 6.537.

28.Navazio AS, Rizzolo P, **Silvestri V**, Valentini V, Zelli V, Zanna I, Masala G, Bianchi S, Tommasi S, Palli D, Ottini L. *EMSY copy number variation in male breast cancers characterized for BRCA1 and BRCA2 mutations*. Breast Cancer Res Treat. 2016 Nov;160(1):181-186. doi: 10.1007/s10549-016-3976-8. IF: 3.626.

29.Chandramouli B, **Silvestri V**, Scarno M, Ottini L, Chillemi G. *Smyd3 open & closed lock mechanism for substrate recruitment: The hinge motion of C-terminal domain inferred from μ-second molecular dynamics simulations*. Biochim Biophys Acta. 2016 Jul;1860(7):1466-74. doi: 10.1016/j.bbagen.2016.04.006. IF: 4.702.

30.**Silvestri V**, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY, Mitchell G, James P, Thull DL, Zorn KK, Carter NJ, Nathanson KL, Domchek SM, Rebbeck TR, Ramus SJ, Nussbaum RL, Olopade OI, Rantala J, Yoon SY, Caligo MA, Spugnesi L, Bojesen A, Pedersen IS, Thomassen M, Jensen UB, Toland AE, Senter L, Andrulis IL, Glendon G, Hulick PJ, Imyanitov EN, Greene MH, Mai PL, Singer CF, Rappaport-Fuerhauser C, Kramer G, Vijai J, Offit K, Robson M, Lincoln A, Jacobs L, Machackova E, Foretova L, Navratilova M, Vasickova P, Couch FJ, Hallberg E, Ruddy KJ, Sharma P, Kim SW; kConFab Investigators, Teixeira MR, Pinto P, Montagna M, Matricardi L, Arason A, Johannsson OT, Barkardottir RB, Jakubowska A, Lubinski J, Izquierdo A, Pujana MA, Balmaña J, Diez O, Ivady G, Papp J, Olah E, Kwong A; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), Nevanlinna H, Aittomäki K, Perez Segura P, Caldes T, Van Maerken T, Poppe B, Claes KB, Isaacs C, Elan C, Lasset C, Stoppa-Lyonnet D, Barjhoux L, Belotti M, Meindl A, Gehrig A, Sutter C, Engel C, Niederacher D, Steinemann D, Hahnen E, Kast K, Arnold N, Varon-Mateeva R, Wand D, Godwin AK, Evans DG, Frost D, Perkins J, Adlard J, Izatt L, Platte R, Eeles R, Ellis S; EMBRACE, Hamann U, Garber J, Fostira F, Fountzilas G, Pasini B, Giannini G, Rizzolo P, Russo A, Cortesi L, Papi L, Varesco L, Palli D, Zanna I, Savarese A, Radice P, Manoukian S, Peissel B, Barile M, Bonanni B, Viel A, Pensotti V, Tommasi S, Peterlongo P, Weitzel JN, Osorio A, Benitez J, McGuffog L, Healey S, Gerdes AM, Ejlertsen B, Hansen TV, Steele L, Ding YC, Tung N, Janavicius R, Goldgar DE, Buys SS, Daly MB, Bane A,Terry MB, John EM, Southey M, Easton DF, Chenevix-Trench G, Antoniou AC, Ottini L. *Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2*. Breast Cancer Res. 2016 Feb 9;18(1):15. doi: 10.1186/s13058-016-0671-y. IF: 6.345.

31.**Silvestri V**, Rizzolo P, Scarnò M, Chillemi G, Navazio AS, Valentini V, Zelli V, Zanna I, Saieva C, Masala G, Bianchi S, Manoukian S, Barile M, Pensotti V, Peterlongo P, Varesco L, Tommasi S, Russo A, Giannini G, Cortesi L, Viel A, Montagna M, Radice P, Palli D, Ottini L. *Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: results from a multicenter study in Italy*. Eur J Cancer. 2015 Nov;51(16):2289-95. doi: 10.1016/j.ejca.2015.07.020. IF: 6.163.

32.Peterlongo P, Catucci I, Colombo M, Caleca L, Mucaki E, Bogliolo M, Marin M, Damiola F, Bernard L, Pensotti V, Volorio S, Dall'Olio V, Meindl A, Bartram C, Sutter C, Surowy H, Sornin V, Dondon MG, Eon-Marchais S, Stoppa-Lyonnet D, Andrieu N, Sinilnikova OM; GENESIS, Mitchell G, James PA, Thompson E; kConFab; SWE-BRCA, Marchetti M, Verzeroli C, Tartari C, Capone GL, Putignano AL, Genuardi M, Medici V, Marchi I, Federico M, Tognazzo S, Matricardi L, Agata S, Dolcetti R, Della Puppa L, Cini G,

Gismondi V, Viassolo V, Perfumo C, Mencarelli MA, Baldassarri M, Peissel B, Roversi G, **Silvestri V**, Rizzolo P, Spina F, Vivanet C, Tibiletti MG, Caligo MA, Gambino G, Tommasi S, Pilato B, Tondini C, Corna C, Bonanni B, Barile M, Osorio A, Benitez J, Balestrino L, Ottini L, Manoukian S, Pierotti MA, Renieri A, Varesco L, Couch FJ, Wang X, Devilee P, Hilbers FS, van Asperen CJ, Viel A, Montagna M, Cortesi L, Diez O, Balmaña J, Hauke J, Schmutzler RK, Papi L, Pujana MA, Lázaro C, Falanga A, Offit K, Vijai J, Campbell I, Burwinkel B, Kvist A, Ehrencrona H, Mazoyer S, Pizzamiglio S, Verderio P, Surralles J, Rogan PK, Radice P. *FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor*. Hum Mol Genet. 2015 Sep 15;24(18):5345-55. doi: 10.1093/hmg/ddv251. IF: 5.985.

33.Ottini L, Rizzolo P, Siniscalchi E, Zijno A, **Silvestri V**, Crebelli R, Marcon F. *Gene promoter methylation and DNA repair capacity in monozygotic twins with discordant smoking habits*. Mutat Res Genet Toxicol Environ Mutagen. 2015 Feb; 779:57-64. doi: 10.1016/j.mrgentox.2015.01.006. IF: 2.254.

34.Ottini L, Rizzolo P, Zanna I, **Silvestri V**, Saieva C, Falchetti M, Masala G, Navazio AS, Capalbo C, Bianchi S, Manoukian S, Barile M, Peterlongo P, Caligo MA, Varesco L, Tommasi S, Russo A, Giannini G, Cortesi L, Cini G, Montagna M, Radice P, Palli D. *Association of SULT1A1 Arg^{213}His polymorphism with male breast cancer risk: results from a multicenter study in Italy*. Breast Cancer Res Treat. 2014 Dec;148(3):623-8. doi: 10.1007/s10549-014-3193-2. IF: 3.940.

35.Richetta AG, **Silvestri V**, Giancristoforo S, Rizzolo P, D'Epiro S, Graziano V, Mattozzi C, Navazio AS, Falchetti M, Calvieri S, Ottini L. *Mutational profiling in melanocytic tumors: multiple somatic mutations and clinical implications*. Oncology. 2014;86(2):104-8. doi: 10.1159/000356878. IF: 2.613.

36.Richetta AG, **Silvestri V**, Giancristoforo S, Rizzolo P, D'Epiro S, Graziano V, Mattozzi C, Navazio AS, Campoli M, D'Amico C, Scarnò M, Calvieri S, Ottini L. *A-1012G promoter polymorphism of vitamin D receptor gene is associated with psoriasis risk and lower allele-specific expression*. DNA Cell Biol. 2014 Feb;33(2):102-9. doi: 10.1089/dna.2013.2217. IF: 2.055.

37.Rizzolo P*, **Silvestri V***, Tommasi S, Pinto R, Danza K, Falchetti M, Gulino M, Frati P, Ottini L. *Male breast cancer: genetics, epigenetics, and ethical aspects*. Ann Oncol. 2013 Nov;24 Suppl 8: viii75-viii82. doi: 10.1093/annonc/mdt316. IF: 6.578 (*co-first authors).

38.Palli D, Rizzolo P, Zanna I, **Silvestri V**, Saieva C, Falchetti M, Navazio AS, Graziano V, Masala G, Bianchi S, Russo A, Tommasi S, Ottini L. *SULT1A1 gene deletion in BRCA2-associated male breast cancer: a link between genes and environmental exposures?* J Cell Mol Med. 2013 May;17(5):605-7. doi: 10.1111/jcmm.12043. IF: 3.698.

39.Ottini L, **Silvestri V**, Saieva C, Rizzolo P, Zanna I, Falchetti M, Masala G, Navazio AS, Graziano V, Bianchi S, Manoukian S, Barile M, Peterlongo P, D'Amico C, Varesco L, Tommasi S, Russo A, Giannini G, Cortesi L, Viel A, Montagna M, Radice P, Palli D. *Association of low-penetrance alleles with male breast cancer risk and clinicopathological characteristics: results from a multicenter study in Italy*. Breast Cancer Res Treat. 2013 Apr;138(3):861-8. doi: 10.1007/s10549-013-2459-4. IF: 4.198.

40.Ottini L, **Silvestri V**, Rizzolo P, Falchetti M, Zanna I, Saieva C, Masala G, Bianchi S, Manoukian S, Barile M, Peterlongo P, Varesco L, Tommasi S, Russo A, Giannini G, Cortesi L, Viel A, Montagna M, Radice P, Palli D. *Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy*. Breast Cancer Res Treat. 2012 Jul;134(1):411-8. doi: 10.1007/s10549-012-2062-0. IF: 4.469.

41.**Silvestri V**, Rizzolo P, Falchetti M, Zanna I, Masala G, Palli D, Ottini L. *Mutation screening of RAD51C in male breast cancer patients*. Breast Cancer Res. 2011 Feb 8;13(1):404. doi: 10.1186/bcr2823. IF: 5.245.

42.Rizzolo P*, **Silvestri V***, Falchetti M, Ottini L. *Inherited and acquired alterations in development of breast cancer*. Appl Clin Genet. 2011 Nov 14; 4:145-58. doi: 10.2147/TACG.S13226. (*co-first authors).

43.**Silvestri V**, Rizzolo P, Falchetti M, Zanna I, Masala G, Bianchi S, Palli D, Ottini L. *Mutation analysis of BRIP1 in male breast cancer cases: a population-based study in Central Italy*. Breast Cancer Res Treat. 2011 Apr;126(2):539-43. doi: 10.1007/s10549-010-1289-x. IF: 4.431.

44.**Silvestri V,** Rizzolo P, Zanna I, Falchetti M, Masala G, Bianchi S, Papi L, Giannini G, Palli D, Ottini L. *PALB2 mutations in male breast cancer: a population-based study in Central Italy*. Breast Cancer Res Treat. 2010 Jul;122(1):299-301. doi: 10.1007/s10549-010-0797-z. IF: 4.859.

45.Ottini L, Capalbo C, Rizzolo P, **Silvestri V**, Bronte G, Rizzo S, Russo A. *HER2-positive male breast cancer: an update*. Breast Cancer (Dove Med Press). 2010 Oct 4; 2:45-58. doi: 10.2147/BCTT.S6519.

Roma, 26/01/2022

Firmato
VALENTINA SILVESTRI